# Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC)

> **NIH NIH U24** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2020 · $559,976

## Abstract

ABSTRACT
In contrast to the decline in mortality in other cancers, the incidence of pancreatic ductal adenocarcinoma
(PDAC) is increasing, and therapeutic approaches, for the most part, have not been successful at improving
survival in patients. Although recent advances in immunotherapy have shown efficacy in various solid cancers,
comparable efficacy in PDAC has been limited by a complex tumor microenvironment (TME) that creates an
immune suppressive milieu ripe for tumor progression. Thus, bold interventions that can overcome immune
barriers in the PDAC TME are urgently needed to reduce the mortality stemming from this recalcitrant disease.
The U01 “Consortium for PDAC Translational Studies on the TME” was created through the National Cancer
Moonshot initiative to accelerate the pace of progress in innovative therapies targeting the TME in PDAC,
especially those geared towards immune-based modalities. Our proposal is in response to the companion U24
RFA to create a resource center for the five funded Consortium sites, which we call Pancreatic Ductal
Adenocarcinoma Translational Resource Center (PATReC). The PATReC will be co-led by Drs. Ignacio
Wistuba and Anirban Maitra, two established molecular pathologists at UT MD Anderson Cancer Center
(UTMDACC) with long-standing expertise in cancer biomarkers, tissue based molecular profiling, and with
respect to one co-leader (AM), specific expertise in PDAC biology, disease models and experimental
therapeutics. They will be supported by an exceptional supporting cast, including Drs. Jack Lee (biostatistics),
Andy Futreal (cancer genomics and computational biology), Jason Roszik (bioinformatics) and Stan Hamilton
(co-leader of the NCI MATCH biorepository). The overall goal is to support the consortium efforts in multiple
areas including: providing an administrative infrastructure for coordinated interactions amongst the U01
awardees; facilitating centralized biospecimen banking and distribution; enabling centralized data storage
capabilities; and credentialed biostatistics and bioinformatics support with the ultimate goal of designing
translationally relevant combination interventions targeting the TME in PDAC. In Aim 1, we will support
administrative coordination amongst the U01 sites by ensuring effective communication, cooperation, and
access to rapid data exchange that will advance the goals of the individual Consortium sites. The PATReC will
serve as the central “hub” for virtual and in-person communication across the entire Consortium. In Aim 2, we
will utilize our unique institutional infrastructure to provide centralized data management services that will be
readily accessible to all Consortium sites via a secure website, and provide bioinformatics and biostatics
services for the analyses and interpretation of data. In Aim 3, we will standardize bio-banking activities and
develop standard operation procedures (SOPs) for biospecimen collection, processing and distribution, as well
as provide acc...

## Key facts

- **NIH application ID:** 10242451
- **Project number:** 4U24CA224020-02
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** ANIRBAN MAITRA
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $559,976
- **Award type:** 4N
- **Project period:** 2017-09-30 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242451

## Citation

> US National Institutes of Health, RePORTER application 10242451, Pancreatic Ductal Adenocarcinoma Translational Resource Center (PATReC) (4U24CA224020-02). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10242451. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*